Genescà, ELazarenkov, AMorgades, MBerbis, GRuiz-Xivillé, NeusGómez-Marzo, PRibera, JJuncà, JGonzález-Pérez, AMercadal, SGuardia, RArtola, M TMoreno, M JMartinez Lopez, JoaquinZamora, LBarba, PGil, CTormo, MCladera, ANovo, APratcorona, MNomdedeu, JGonzález-Campos, JAlmeida, MCervera, JMontesinos, PBatlle, MVives, SEsteve, JFeliu, ESolé, FOrfao, ARibera, J M2018-11-142018-11-142018-07-24J Hematol Oncol. 2018; 11 (11) : 96.1756-8722http://hdl.handle.net/20.500.13003/9207http://hdl.handle.net/20.500.12105/6591Recurrent deletions of the CDKN2A/ARF/CDKN2B genes encoded at chromosome 9p21 have been described in both pediatric and adult acute lymphoblastic leukemia (ALL), but their prognostic value remains controversial, with limited data on adult T-ALL. Here, we investigated the presence of homozygous and heterozygous deletions of the CDKN2A/ARF and CDKN2B genes in 64 adult T-ALL patients enrolled in two consecutive trials from the Spanish PETHEMA group. Alterations in CDKN2A/ARF/CDKN2B were detected in 35/64 patients (55%). Most of them consisted of 9p21 losses involving homozygous deletions of the CDKNA/ARF gene (26/64), as confirmed by single nucleotide polymorphism (SNP) arrays and interphase fluorescence in situ hybridization (iFISH). Deletions involving the CDKN2A/ARF/CDKN2B locus correlated with a higher frequency of cortical T cell phenotype and a better clearance of minimal residual disease (MRD) after induction therapy. Moreover, the combination of an altered copy-number-value (CNV) involving the CDKN2A/ARF/CDKN2B gene locus and undetectable MRD (≤ 0.01%) values allowed the identification of a subset of T-ALL with better overall survival in the absence of hematopoietic stem cell transplantation.engVoRhttp://creativecommons.org/licenses/by/4.0/CDKN2A/ARFCDKN2BMRDPrognosisT-ALLAtribución 4.0 Internacional300416621119610.1186/s13045-018-0639-81756-8722Journal of hematology & oncologyopen accessGenes p16Inhibidor p16 de la Quinasa Dependiente de CiclinaLeucemia-Linfoma Linfoblástico de Células T PrecursorasProteína p14ARF Supresora de TumorHumanosPronósticoInhibidor p15 de las Quinasas Dependientes de la CiclinaEliminación de Gen2-s2.0-85050852307439693600001L623158983